This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Peptides & Oligonucleotides

CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development - WHITEPAPER


Download exclusive whitepaper

Optimization of Chemistry, Manufacturing, and Control (CMC) activities are essential to accelerating development and manufacture across the product lifecycle of peptide, oligo and mRNA therapeutics.

This whitepaper looks at different approaches that support accelerated clinical development, manufacture and ultimately approval, including:

- Peptides, a unique class of compounds
- Safety and delivery of oligonucleotides
- FDA and EMA guidelines
- mRNAs: towards the future of protein replacement therapy

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. 

ABOUT THE AUTHOR: Catarina Carrão, biochemist by degree, worked as a biomedical researcher at Max F. Perutz Laboratories, Yale Cardiovascular Center at Yale University School of Medicine, and the Center Cardiovascular Research (CCR) at Charité Medical University.

Have any questions or interested in sponsoring future content? Email

Log in or Create an Informa Connect Account to Access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.